MET Pipeline

NuBiyota is developing a pipeline of multi-strain microbiome therapeutic composition candidates to treat a range of medical conditions and diseases, using its proprietary Microbial Ecosystem Therapeutics platform.
Asset Indication Pre-clinical IND Ph1 Ph2 Ph3


MET-4 PD-1 combo-therapy

Metabolic Disease

MET-3 Hypertriglyceridemia (HTG)

GI Disorder/rCDI (recurrent Clostridioides Difficile Infection)

MET-2 Ulcerative colitis (UC)
MET-2 Recurrent C.difficile infection (rCDI)

CNS Disease

MET-2 Depression, Anxiety
The MET 3 phase II study is in the US all other studies are done in Canada.